02496.HK
Wuhan YZY Biopharma Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.30
−8.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 84.8M | 65.1M | 107.8M | 11.9M | 2.3M |
| Cost of Revenue | 71.0M | 59.0M | 22.7M | — | — |
| Gross Profit | 13.8M | 6.2M | 85.1M | 11.9M | 2.3M |
| Operating Expenses | |||||
| R&D Expense | 86.9M | 73.2M | 165.0M | 154.5M | 157.3M |
| SG&A Expense | 26.0M | 20.9M | 14.9M | 22.2M | 20.5M |
| General & Admin Expense | 17.4M | — | 14.4M | 22.2M | 8.9M |
| Selling & Marketing Expense | — | — | 512.0K | — | — |
| Other Expenses | — | — | 3.2M | 664.9K | — |
| Total Operating Expenses | 112.9M | 94.1M | 183.1M | 177.4M | 177.9M |
| Cost and Expenses | 183.9M | 153.1M | 205.8M | 177.4M | 164.5M |
| Operating Income (EBIT) | (99.1M) | (87.9M) | (98.0M) | (177.4M) | (175.6M) |
| Non-Operating | |||||
| Interest Income | 791.9K | 739.4K | 2.6M | 1.3M | 283.0K |
| Interest Expense | 4.4M | 4.8M | 4.1M | 2.4M | 2.5M |
| Net Interest Income | (5.3M) | (4.1M) | (1.5M) | (1.3M) | (2.2M) |
| Other Non-Op Income/Expense | 1.8M | 5.4M | 402.0K | (14.3M) | (13.3M) |
| Non-Operating Income (excl Interest) | (4.9M) | — | (4.5M) | (12.0M) | — |
| EBT (Pre-Tax Income) | (97.2M) | (82.5M) | (97.6M) | (191.0M) | (188.9M) |
| Income Tax Expense | — | — | — | 19.9M | — |
| Bottom Line | |||||
| Net Income | (97.2M) | (82.5M) | (97.6M) | (191.0M) | (188.9M) |
| Earnings from Cont. Ops | (97.2M) | (82.5M) | (97.6M) | (210.9M) | (188.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (97.2M) | (82.5M) | (97.6M) | (210.9M) | (188.9M) |
| Per Share | |||||
| Basic EPS | (HK$0.50) | (HK$0.42) | (HK$0.50) | (HK$1.14) | (HK$0.98) |
| Diluted EPS | (HK$0.50) | (HK$0.42) | (HK$0.50) | (HK$1.14) | (HK$0.98) |
| Revenue Per Share | HK$0.44 | HK$0.34 | HK$0.56 | HK$0.06 | HK$0.01 |
| Shares | |||||
| Basic Shares Outstanding | 193.8M | 193.8M | 193.8M | 185.1M | 193.0M |
| Diluted Shares Outstanding | 193.8M | 193.8M | 193.8M | 185.1M | 193.0M |
| Profitability Metrics | |||||
| EBITDA | (89.3M) | (83.6M) | (86.9M) | (158.4M) | (169.2M) |
| D&A | 5.0M | 4.3M | 6.6M | 6.4M | 6.3M |
| EBIT | (94.2M) | (87.9M) | (93.5M) | (164.8M) | (175.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025